An antiretroviral drug released from an experimental vaginal ring to protect women against HIV is absorbed in low concentrations into breastmilk, according to researchers from the NIH-funded Microbicide Trials Network. The team touted data today from a Phase I trial of the device at the 9th IAS Conference on HIV Sciences in Paris.
The dapivirine ring was studied for 14 days in women who were no longer nursing their babies, but were still lactating. Use of the drug-device combo was also linked to low levels of dapivirine in the women’s plasma.
Get the full story at our sister site, Drug Delivery Business News.
The post Study: Antiretroviral drug-eluting ring safe in breastfeeding mothers appeared first on MassDevice.